Literature DB >> 30637330

Regulatory T Cells in Gynecologic Cancer.

Yang Ou1, Martin J Cannon2, Mayumi Nakagawa1.   

Abstract

Increasing evidence supports that regulatory T cells (Tregs) within the tumor, tumor draining lymph nodes, ascites and peripheral blood of patients with cancer are associated with poor prognosis. Tregs are important mediators of active immune evasion in cancer. In this review, the potential mechanisms of Treg actions and the roles of Tregs specifically in the tumor microenvironment derived from three types of gynecological cancers, cervical, vulvar and ovarian, are described. The correlations between Tregs and clinical immunotherapeutic study outcomes are discussed. Successful modulation of Tregs would likely have significant impact on the effectiveness of immunotherapeutic treatments in cancer patients.

Entities:  

Keywords:  Tregs; cancer; cervical; ovarian; vulvar

Year:  2018        PMID: 30637330      PMCID: PMC6329475     

Source DB:  PubMed          Journal:  MOJ Immunol        ISSN: 2373-4442


  9 in total

1.  Pretreatment Immune Status, Predicts Response to Definite Chemo Radiotherapy in Advanced Stages of Cervical Cancer Patients.

Authors:  Swati Garg; Usha Shekhawat; Rajaat Vohra; Reshu Gupta
Journal:  J Obstet Gynaecol India       Date:  2022-02-24

2.  Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).

Authors:  Diane M Da Silva; Danielle M Enserro; Jyoti S Mayadev; Joseph G Skeate; Koji Matsuo; Huyen Q Pham; Heather A Lankes; Katherine M Moxley; Sharad A Ghamande; Yvonne G Lin; Russell J Schilder; Michael J Birrer; W Martin Kast
Journal:  Clin Cancer Res       Date:  2020-08-18       Impact factor: 12.531

Review 3.  Biomarkers for immunotherapy for treatment of glioblastoma.

Authors:  John P Lynes; Anthony K Nwankwo; Hannah P Sur; Victoria E Sanchez; Kwadwo A Sarpong; Oluwatobi I Ariyo; Gifty A Dominah; Edjah K Nduom
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

Review 4.  The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.

Authors:  Denisa Baci; Annalisa Bosi; Matteo Gallazzi; Manuela Rizzi; Douglas M Noonan; Alessandro Poggi; Antonino Bruno; Lorenzo Mortara
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

Review 5.  Current Ovarian Cancer Maintenance Strategies and Promising New Developments.

Authors:  Vinaya Gogineni; Susan Morand; Hannah Staats; Rachel Royfman; Monika Devanaboyina; Katelyn Einloth; Danielle Dever; Laura Stanbery; Phylicia Aaron; Luisa Manning; Adam Walter; Gerald Edelman; Lance Dworkin; John Nemunaitis
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

Review 6.  Immunotherapeutic Approaches for Glioblastoma Treatment.

Authors:  Nasser K Yaghi; Mark R Gilbert
Journal:  Biomedicines       Date:  2022-02-11

Review 7.  Progress in Applicability of Scoring Systems Based on Nutritional and Inflammatory Parameters for Ovarian Cancer.

Authors:  Juan Mu; Yue Wu; Chen Jiang; Linjuan Cai; Dake Li; Jian Cao
Journal:  Front Nutr       Date:  2022-04-08

8.  Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.

Authors:  Gwan Hee Han; Ilseon Hwang; Hanbyoul Cho; Kris Ylaya; Jung-A Choi; Hyunja Kwon; Joon-Yong Chung; Stephen M Hewitt; Jae-Hoon Kim
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

Review 9.  Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells.

Authors:  Rhiane Moody; Kirsty Wilson; Anthony Jaworowski; Magdalena Plebanski
Journal:  Cancers (Basel)       Date:  2020-03-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.